About cytomx therapeutics inc - CTMX
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.
CTMX At a Glance
CytomX Therapeutics, Inc.
151 Oyster Point Boulevard
South San Francisco, California 94080-1913
| Phone | 1-605-515-3185 | Revenue | 76.20M | |
| Industry | Pharmaceuticals: Major | Net Income | -17,368,000.00 | |
| Sector | Health Technology | Employees | 69 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
CTMX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 7.711 |
| Price to Book Ratio | 7.323 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -25.005 |
| Enterprise Value to Sales | 5.968 |
| Total Debt to Enterprise Value | 0.009 |
CTMX Efficiency
| Revenue/Employee | 1,104,362.319 |
| Income Per Employee | -251,710.145 |
| Receivables Turnover | 30.323 |
| Total Asset Turnover | 0.554 |
CTMX Liquidity
| Current Ratio | 3.087 |
| Quick Ratio | 3.087 |
| Cash Ratio | 2.94 |
CTMX Profitability
| Gross Margin | 98.194 |
| Operating Margin | -25.674 |
| Pretax Margin | -22.48 |
| Net Margin | -22.792 |
| Return on Assets | -12.625 |
| Return on Equity | -35.246 |
| Return on Total Capital | -16.822 |
| Return on Invested Capital | -33.793 |
CTMX Capital Structure
| Total Debt to Total Equity | 4.282 |
| Total Debt to Total Capital | 4.107 |
| Total Debt to Total Assets | 2.78 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |